HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2008; **23**: 735–736.

Author Index

Adams, D. H., 267
Akdeniz, F., 313
Akhondzadeh, S., 79
Alessio, D. D., 1
Allgulander, C., 519
Altintoprak, A. E., 313
Amiri, A., 79
Anderer, P., 243
Anderson, C., 333
Andreoli, S., 417
Angriman, M., 437
Arai, H., 139
Arolt, V., 587
Arranz, B., 275
Arranz, M. J., 107
Assandri, A., 243
Azzoni, A., 661

Böckermann, I., 587
Baggaley, M., 201
Baldessarini, R. J., 95, 447
Baldwin, D., 527
Bandrés, F., 533
Baune, B. T., 587
Becker, S., 31
Begg, D. P., 129
Begum, H., 621
Bleich, S., 171
Bogerts, B., 549
Boulon, S., 471
Bowden, C. L., 87
Boyle, J., 385, 555, 605
Bozkurt, A., 321
Bröcheler, A., 31
Breier, A., 267
Briley, M., 527
Broadbear, J. H., 681
Buchner, H., 31
Bueno, O. F. A., 183
Burrows, G. D., 653
Busner, J., 629

Cansever, A., 321
Carlson, J., 519
Centorrino, F., 447
Chawla, B., 211, 275
Chen, R.-y., 465
Chen, Z.-h., 465
Cho, S.-C., 715
Choi, E. Y., 61
Clark, D. A., 107
Close, S., 267
Cluver, J., 160
Corser, B. C., 13
Cortese, S., 437
Cortner, C., 513
Coskunol, H., 313
Cougnard, A., 471
Croft, R. J., 151, 231, 301, 355
Cromer, J., 425
Culic, S., 243

Díez-Durán, S., 533
Dannlowski, U., 587
Davidson, J., 519
Dawkins, L., 621
Dawson, J., 605
de Castro, E., 533
de Haan, L., 275
de Leon, J., 107
Demazières, A., 693
Demisch, L., 43
Derakhshan, M.-K., 79
Di Giannantonio, M., 417
Di Nicola, M., 417
DiGiacomo, G., 475
Domschke, K., 587
Doruk, A., 321
Downing, A. M., 267
Dunk, L., S27
Dursun, S. M., S1, S15

Earleywine, M., 475, 487
Ebe, K., 399
Ellis, K. A., 151
Erickson, J. S., 519
Evers, S., 587

Farmen, M., 267
Fernández-Santander, A., 533
Fisk, J. E., 495
Flanagan, R. J., S27, S43
Fonseca, M., 87
Formisano, E., 221
Fredrickson, A., 425
Frey, B. N., 87

Gómez-Gallego, F., 533
Germain, A., 571
Ghoreishi, A., 79
Giegling, I., 115
González, M., 533
Gould, J. L., 513
Grosser, O., 549
Guerdjikova, A. I., 1
Guijarro, J., 533
Guille, V., 231, 301
Gurtman, C. G., 681

Haddad, P. M., S1, S15
Hajiazim, M., 79
Hallam, K. T., 129
Hartford, J., 519
Harvey, B. H., 371
Hatch, J. P., 87
Heberlein, A., 171
Hegerl, U., 115
Heinzel, A., 549
Hetzel, G., 587
Higuchi, H., 121, 217
Hillemacher, T., 171
Hindmarch, I., 605
Hoffmann, V. P., 275
Holtmann, M., 291
Hori, H., 327, 707
Horikawa, E., 139
Horne, J. A., 333
Houston, J. P., 267
Hudson, J. I., 1
Hunt, N., 409
Huo, Y.-x., 465

Ignatiadis, S., 653
Iidaka, T., 399
Ikenouchi-Sugita, A., 707
Illic, S., 231
Inoue, K., 121
Ishigooka, J., 217
Ishihara, R., 399
Itoh, K., 121
Itoh, M., 139
Iwamoto, K., 399

Jacob, N., 693
James, J. E., 669
Janiri, L., 417
Jerrell, J. M., 53, 283, 595
Johnsen, S., 385, 605
Joo, Y. H., 61
Juckel, G., 115

Kakihara, S., 327
Kamata, M., 121, 217
Karagianis, J., 275
Karakatsanis, N. A., 337
Karapoulios, E., 337
Karlidere, T., 321
Kashima, H., 455
Kawamura, Y., 399
Kawohl, W., 31, 115
Keane, M. A., 669
Keck Jr, P. E., 1
Kerwin, R. W., 107
Khodaie-Ardakani, M.-R., 79
Kim, B., 61
Kim, B.-N., 715
Kim, C. Y., 61
Kim, J.-M., 615

Copyright © 2008 John Wiley & Sons, Ltd.

Kim, J.-W., 715
Kim, S.-W., 615
Kim, Y., 715
Kinoshita, T., 647
Kitapcioglu, G., 313
Konstantakopoulos, G., 337
Kontoangelos, K. A., 337
Kornhuber, J., 171
Kotwal, R., 1
Koury, M. A., 513
Kouzoupis, A. V., 337
Kunert, H. J., 31
Kupfer, D. J., 571
Kuypers, K. P. C., 221
Kwentoh, M.-L., 160

Lake, K., 1
Landgraf, M., 43
Lavender, J. M., 487
Leonard, B. E., 68, 341, 537, 538, 723
Leung, S., 151, 301
Lewis, M., 425
Looby, A., 487
Lucia, A., 533
Luxton-Andrew, H., 211

Mackin, P., S3
Maguire, G. A., 275
Manzano, G. M., 183
Martinotti, G., 417
Maruff, P., 425, 653
Maruyama, M., 139
Masdrakis, V. G., 337
Mavrogiorgou, P., 115
Mayleben, D., 13
McDonald, K., 555
McElroy, S. L., 1
McHale, S., 409
McIntyre, R. S., 283
Mei, H.-b., 465
Mochizuki, H., 139
Molero, P., 107
Monkul, E. S., 87
Montgomery, C., 495
Mooney, M., 21
Moreno, R. A., 527
Morishita, S., 647
Mulert, C., 115

Nakajima, S., 455
Nakamura, J., 327, 707
Nakamura, Y., 399
Nannipieri, F., 243
Nathan, P. J., 151, 231, 301, 355
Nejatisafa, A.-A., 79
Nelson, E., 1
Nery, F. G., 87
Nir, T., 693
Noda, A., 399
Noda, Y., 399
Nomura, K., 455
Noorbala, A.-A., 79
Norman, T. R., 129, 653
Norra, C., 31
Northoff, G., 549

O'Neill, B. V., 151, 231, 301, 355
Okamura, N., 139
Oliver, C., 151
Olmstead, R. E., 513
Olver, J. S., 129, 653
Otmani, S., 693
Otto, H., 549
Oulis, P., 337
Ozaki, N., 121, 399
Ozgen, F., 321
Ozmenler, N. K., 321
Ozsahin, A., 321

Palmer, C., 151
Papadimitriou, G. N., 337
Park, K.-H., 615
Parrott, A. C., 621
Pelic, C., 160
Perahia, D., 519
Perry, R., 95
Phan, K. L., 231, 301
Pike, J., 95
Poeppel, T. D., 549
Pogarell, O., 115
Pollack, M. H., 519
Pompéia, S., 183
Poustka, F., 43, 291, 438
Pradella-Hallinan, M., 183

Raja, M., 661
Ramaekers, J. G., 221
Ramirez, P. M., 595
Raskin, J., 519
Raznahan, M., 79
Redman, J. R., 681
Roach, J., 385
Rosini, S., 243
Roth, T., 13
Rothermundt, M., 587
Rubens, R., 385
Rujescu, D., 115
Russell, J. M., 519

Saiz, P. A., 107
Sakurada, Y., 139
Saletu-Zyhlarz, G. M., 243
Saletu, B., 243
Santiago, C., 533
Sarchiapone, M., 417
Sato, K., 121
Schmitt, M., 43
Schneider, N. G., 513
Scholes, K. E., 301
Shin, I.-S., 615
Shin, M.-S., 715
Singh, N. N., 13
Skene, D. J., 605
Snyder, P. J., 425
Soar, K., 621
Soares, J. C., 87
Sofuoglu, M., 21
Song, K., 61
Stadler, C., 43
Staner, C., 693
Staner, L., 693
Stanley, N., 605
Steinke, R., 549
Sugita, A., 327
Susce, M. T., 107
Sutcigil, L., 321
Suzuki, T., 121, 455

Takahashi, H., 121, 217
Takahashi, M., 399
Takeuchi, H., 455
Talamo, A., 447
Tanabe, A., 455
Targum, S. D., 629
Tashiro, M., 139
Taylor, A. H., 193, 725
Thomas, E., 425
Treuer, T., 275
Trick, L., 385, 555

Uchida, H., 455
Uchiyama, Y., 399
Ueda, N., 327, 707
Umene-Nakano, W., 327, 707
Uzun, O., 321

Van Dam, N. T., 475
van de Ven, V., 221
Van Rensburg, K. J., 193
Verdoux, H., 471

Wöckel, L., 291
Wang, G.-h., 465
Wang, H.-l., 465
Wang, X.-p., 465
Watanabe, K., 455
Watanuki, S., 139
Waters, A. J., 21
Welge, J. A., 1
Wesnes, K. A., 151
Wingen, M., 221
Winter, C., 115
Wohlreich, M. M., 519
Wolzt, M., 243

Yagi, G., 455
Yanai, K., 139
Yang, M.-h., 465
Yetkin, S., 321
Yoon, J.-S., 615
Yoshida, K., 121, 217, 399
Yoshimura, R., 327, 707
Youn, T., 615
Young, A. H., 629

Zepf, F. D., 43, 291, 438
Zisapel, N., 693
Zorlu, N., 313
Zunta-Soares, G. B., 87

Copyright © 2008 John Wiley & Sons, Ltd.

HUMAN PSYCHOPHARMACOLOGY
Hum Psychopharmacol Clin Exp 2008; **23**: 737–738.

Keyword Index

5-HT, 291
α_{1A}-adrenergic receptor, 107

ABIO-08/01, 243
abstinence, 621
actigraphy, 605
ADHD, 43, 291
adherence, 95
adjunctive treatment, 587
adolescents, 53, 283
adverse effects, 95
adverse events, 283
age, 647
aggression, 43
agitation, 587
agranulocytosis: drug-induced, S27
alcohol dependence, 313
alcohol, 417
amino acid depletion, 301
amitriptyline, 313, 399
anti-inflammatory agents, 87
antidepressant, 129, 371, 647
antidepressants, S15, 399, 661
antiemetic, 615
antihistamine, 139, 615
antihistamines, 555
antipsychotic polypharmacy, 455
antipsychotic, 267
antipsychotics, S15, 283, 661
anxiolytic, 243
association, 115
attention, 151, 193
atypical antipsychotic, 201, 275
auditory evoked potentials, 31
augmentation, 217, 653

BDNF, 707
benzodiazepine dependence, 171, 337
benzodiazepine discontinuation, 337
benzodiazepine withdrawal, 171
benzodiazepine, 605
benzodiazepines, 183
binge-eating disorder, 1
biological marker, 355
bipolar depression, 87
bipolar disorder, 53, 87, 95, 447

caffeine, 327, 669
cannabis-associated problems, 487
cannabis, 409, 475, 487
cardiovascular system, S3
car driving, 139
catechol-*O*-methyltransferase, 121
catecholamines, 301
CBCL-PBD-profile, 291
celecoxib, 87
central executive, 183
cerebral blood flow, 139
CGI, 629
children, 53, 283
chronotherapy, 571
cigarette smoking, 327
circadian rhythm, 129
circadian rhythms, 571
citalopram, 231
clinical practice, 471
clozapine, 715
clozapine: neutropenia/agranulocytosis, S27
CNS trials, 629
co-morbidity, 313
cognition enhancer, 243
cognition, 151, 385, 653
cognitive function, 399, 425, 465
cognitive functions, 693
cognitive performance, 605
combination nicotine treatment, 513
COMT, 115
concentration, 193
cortisol, 129
cotinine, 327
craving, 513
cyclooxygenase-2 inhibitors, 87

declarative memory, 151
depression, 217, 321, 355, 527, 653
depressive disorder, 313, 629
desmethylsertraline, 707
differential item functioning, 487
dipole source analysis, 31
disintegrating, 275
dissolving, 275
dopamine, 115, 301, 355, 615
DRD3, 61
driving ability, 385
driving performance, 399
driving simulator, 681, 693
dual diagnosis, 417
duloxetine, 519

early onset schizophrenia, 715
ecstasy, 495
EEG, 669
effect size, 425
efficacy, 519
elderly, 519, 693
escitalopram, 1, 231
eszopiclone, 385
evoked potentials, 301
executive function, 409, 495
extrapyramidal symptoms, S15

fatal poisoning-antidepressants, S43
fatal poisoning-antipsychotics, S43
fatal poisoning-suicide, S43
functioning outcomes, 595

GABA-A, 549
GABA, 371
gender, 471
generalized anxiety disorder, 519
genetic association, 107, 267
glutamate, 151, 371
glycine, 151

haplotype analysis, 115
heart muscle, S3
hospitalization rate, 715
HTR2A, 61

I-123-iomazenil, 549
immediate memory, 621
impaired performance, 139
impairment, 555
impulsivity, 43
inclusion exclusion criteria, 447
insomnia, 385

LDAEP, 115
long-term treatment, 95
lorazepam, 183
loudness dependence auditory evoked potential, 231
loudness dependence auditory evoked potentials, 301
loudness dependence of auditory evoked potential (LDAEP), 355
loudness dependence, 31
low-resolution brain electromagnetic tomography, 243

maintenance, 95
major depression, 371, 587, 647

Copyright © 2008 John Wiley & Sons, Ltd.

major depressive disorder, 121
mania, 447
marijuana, 409
MDMA, 495
medial prefrontal cortex, 549
melancholia, 217
melatonin, 129, 571, 693
memory, 495
metabolic encephalopathy, 371
metabolic monitoring, 471
milnacipran, 121, 527
mirtazapine, 313, 321, 615
modafinil, 21, 681
Monoamine Oxidase Inhibitor-B, 79
mood stabilizers, 661
mood, 669
MOTN insomnia, 13

N1/P2 component, 31
neuroendocrinology, 171
neuroleptic malignant syndrome, S15
neuropsychological changes, 595
neutropenia: drug-induced, S27
neutropenia, 715
nicotine replacement treatments, 513
nicotine withdrawal, 21
nicotine, 21
nitric oxide, 371
NMDA receptor, 151, 355

obesity, 1
obsessive-compulsive, 1
olanzapine, 211, 217, 275, 455, 595
onset of action, 371
open-label clinical trial, 455
orally disintegrating tablets, 211
orthostatic hypotension, S3

paroxetine, 399
pediatric bipolar disorder, 291
performance, 183, 385, 555, 669
PET, 139
pharmaco-ERP study, 243
pharmaco-fMRI, 221
pharmacodynamics, 13
pharmacoepidemiology, 283
pharmacogenomics, 267, 533
pharmacokinetics, 13
pharmacotherapy, 53
placebo-caffeine, 333
polymorphism, 121, 267
poor metabolizer, 533
preference, 513
pregabalin, 337
prolactin, 201
prophylaxis, 95
proportional impairment ratio, 555
prospective memory, 409
psychomotor performance, 605
psychosis, 475
psychotropic drugs, S3
psychotropic medication: blood dyscrasia, S27

QSU-Brief, 193
quetiapine, 417, 587, 653
quitting, 193

randomized clinical trial, 1
randomized-clinical trial, 447
randomized-controlled trials, 87
rapid tryptophan depletion, 291
reaction time, 291, 333
refractory depression, 707
relapse prevention, 417
response, 267
restless legs syndrome, 615
risperidone, 61, 107, 327, 455, 465, 595, 707
RTD, 43

S-ketamine, 549
schizophrenia, 61, 79, 151, 201, 211, 327, 465, 533, 595
Schizotypal Personality Questionnaire, 475
schizotypy, 475
scopolamine, 425
scoring criteria, 629
second-generation antipsychotic, 471
sedation, 555
seizures, S15
selective serotonin reuptake inhibitor, 231
selegiline, 79
self-assessment, 681
serotonin (5-HT), 355
serotonin reuptake inhibitors, 1
serotonin, 31, 43, 115, 221, 231, 301, 371
serotonin toxicity, S15
sertraline, 231, 647, 707
severe mental illness, S3
sex, 647
sexual dysfunction, 321, 527
sexual function and enjoyment questionnaire, 527
sexual function, 201
SFEQ, 527
side-effects, 107
sleep deprivation, 681
sleep disturbances depression, 571
sleep restriction, 669
sleep, 571, 587
sleepiness, 333
smoking, 621
SPECT, 549
SSRI, 647
Stroop, 193
suicide, 661
sustained attention, 221
symptomatology outcomes, 595

temperature, 129
tolerability, 519
traditional Chinese medicine, 465
tramadol, 615
treatment-refractory schizophrenia, 455
treatment, 661
tricyclic antidepressant, 217
tryptophan depletion, 31
tryptophan, 43
tyrosine hydroxylase, 121

urge to smoke, 193

venlafaxine, 129
verbal fluency, 409
verbal learning, 621
visual abilities, 183
visual memory, 409

walking, 193
warm-supplementing kidney yang (WSKY) capsule, 465
weight loss, 211
weight, 275
withdrawal, 513, 669
working memory, 151, 183

zolpidem, 693

Copyright © 2008 John Wiley & Sons, Ltd.

CONTENTS

Volume 23 Issue Nos 1–8 & Supplement 1

HUMAN PSYCHOPHARMACOLOGY

Issue No. 1 January 2008

Research Articles

High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial: **A. I. Guerdjikova, S. L. McElroy, R. Kotwal, J. A. Welge, E. Nelson, K. Lake, D. D' Alessio, P. E. Keck Jr and J. I. Hudson** 1

Daytime pharmacodynamic and pharmacokinetic evaluation of low-dose sublingual transmucosal zolpidem hemitartrate: **T. Roth, D. Mayleben, B. C. Corser and N. N. Singh** 13

Modafinil and nicotine interactions in abstinent smokers: **M. Sofuoglu, A. J. Waters and M. Mooney** 21

Loudness dependence of evoked dipole source activity during acute serotonin challenge in females: **C. Norra, S. Becker, A. Bröcheler, W. Kawohl, H. J. Kunert and H. Buchner** 31

Serotonergic functioning and trait-impulsivity in attention-deficit/hyperactivity-disordered boys (ADHD): influence of rapid tryptophan depletion: **F. D. Zepf, C. Stadler, L. Demisch, M. Schmitt, M. Landgraf and F. Poustka** 43

Pharmacotherapy in the community-based treatment of children with bipolar I disorder: **J. M. Jerrell** ... 53

Could HTR2A T102C and DRD3 Ser9Gly predict clinical improvement in patients with acutely exacerbated schizophrenia? Results from treatment responses to risperidone in a naturalistic setting: **B. Kim, E. Y. Choi, C. Y. Kim, K. Song and Y. H. Joo** 61

Book Reviews

Fundamentals of Clinical Psychopharmacology: **B. E. Leonard** 68

Psychiatric Disorders and Diabetes Mellitus: **B. E. Leonard** 68

Current Awareness in Human Psychopharmacology 715

Issue No. 2 March 2008

Research Articles

Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study: **A. Amiri, A.-A. Noorbala, A.-A. Nejatisafa, A. Ghoreishi, M.-K. Derakhshan, M.-R. Khodaie-Ardakani, M. Hajiazim, M. Raznahan and S. Akhondzadeh** 79

Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study: **F. G. Nery, E. S. Monkul, J. P. Hatch, M. Fonseca, G. B. Zunta-Soares, B. N. Frey, C. L. Bowden and J. C. Soares** 87

Factors associated with treatment nonadherence among US bipolar disorder patients: **R. J. Baldessarini, R. Perry and J. Pike** 95

An investigation of the α_{1A}-adrenergic receptor gene and antipsychotic-induced side-effects: **P. A. Saiz, M. T. Susce, D. A. Clark, R. W. Kerwin, P. Molero, M. J. Arranz and J. de Leon** 107

Association of catechol-O-methyltransferase variants with loudness dependence of auditory evoked potentials: **G. Juckel, W. Kawohl, I. Giegling, P. Mavrogiorgou, C. Winter, O. Pogarell, C. Mulert, U. Hegerl and D. Rujescu** 115

Influence of the tyrosine hydroxylase val81met polymorphism and catechol-*O*-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran: **K. Yoshida, H. Higuchi, H. Takahashi, M. Kamata, K. Sato, K. Inoue, T. Suzuki, K. Itoh and N. Ozaki** 121

An investigation of the effect of immediate and extended release venlafaxine on nocturnal melatonin and cortisol release in healthy adult volunteers: **K. T. Hallam, D. P. Begg, J. S. Olver and T. R. Norman** 129

Effects of a sedative antihistamine, D-chlorpheniramine, on regional cerebral perfusion and performance during simulated car driving: **M. Tashiro, Y. Sakurada, H. Mochizuki, E. Horikawa, M. Maruyama, N. Okamura, S. Watanuki, H. Arai, M. Itoh and K. Yanai** 139

The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls: **C. Palmer, K. A. Ellis, B. V. O'Neill, R. J. Croft, S. Leung, C. Oliver, K. A. Wesnes and P. J. Nathan** 151

Book Reviews
Severe Dementia: **M.-L. Kwentoh** 160

ASCP Model Psychopharmacology Curriculum for Psychiatric Residency Programs, Training Directors, and Teachers of Psychopharmacology: **C. Pelic and J. Cluver** 160

Current Awareness in Human Psychopharmacology 163

Issue No. 3 April 2008

Review Article
Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy: **A. Heberlein, S. Bleich, J. Kornhuber and T. Hillemacher** 171

Research Articles
Effects of lorazepam on visual perceptual abilities: **S. Pompéia, M. Pradella-Hallinan, G. M. Manzano and O. F. A. Bueno** 183

The effects of acute exercise on cognitive functioning and cigarette cravings during temporary abstinence from smoking: **K. J. Van Rensburg and A. H. Taylor** 193

Review Article
Sexual dysfunction in schizophrenia: focus on recent evidence: **M. Baggaley** 201

Research Article
Long-term weight loss observed with olanzapine orally disintegrating tablets in overweight patients with chronic schizophrenia. A 1 year open-label, prospective trial: **B. Chawla and H. Luxton-Andrew** .. 211

Short Communication
Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series: **H. Takahashi, M. Kamata, K. Yoshida, H. Higuchi and J. Ishigooka** 217

Research Articles
Sustained attention and serotonin: a pharmaco-fMRI study: **M. Wingen, K. P. C. Kuypers, V. van de Ven, E. Formisano and J. G. Ramaekers** 221

An examination of acute changes in serotonergic neurotransmission using the loudness dependence measure of auditory cortex evoked activity: effects of citalopram, escitalopram and sertraline: **V. Guille, R. J. Croft, B. V. O'Neill, S. Illic, K. L. Phan and P. J. Nathan** 231

Double-blind, placebo-controlled, multiple-ascending-dose study on the effects of ABIO-08/01, a novel anxiolytic drug, on perception and cognition, utilizing event-related potential mapping and low-resolution brain electromagnetic tomography: **P. Anderer, B. Saletu, M. Wolzt, S. Culic, A. Assandri, F. Nannipieri, S. Rosini and G. M. Saletu-Zyhlarz** 243

Current Awareness in Human Psychopharmacology 255

Issue No. 4 June 2008

Research Article

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder: **D. H. Adams, S. Close, M. Farmen, A. M. Downing, A. Breier and J. P. Houston** 267

Review Article

Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain: **J. Karagianis, V. P. Hoffmann, B. Arranz, T. Treuer, G. A. Maguire, L. de Haan and B. Chawla** ... 275

Research Articles

Adverse events in children and adolescents treated with antipsychotic medications: **J. M. Jerrell and R. S. McIntyre** 283

Diminished 5-HT functioning in CBCL pediatric bipolar disorder-profiled ADHD patients versus normal ADHD: susceptibility to rapid tryptophan depletion influences reaction time performance: **F. D. Zepf, L. Wöckel, F. Poustka and M. Holtmann** 291

Effects of selective and combined serotonin and dopamine depletion on the loudness dependence of the auditory evoked potential (LDAEP) in humans: **B. V. O'Neill, V. Guille, R. J. Croft, S. Leung, K. E. Scholes, K. L. Phan and P. J. Nathan** 301

Effectiveness and tolerability of mirtazapine and amitriptyline in alcoholic patients with co-morbid depressive disorder: a randomized, double-blind study: **A. E. Altintoprak, N. Zorlu, H. Coskunol, F. Akdeniz and G. Kitapcioglu** 313

Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors: **N. K. Ozmenler, T. Karlidere, A. Bozkurt, S. Yetkin, A. Doruk, L. Sutcigil, A. Cansever, O. Uzun, F. Ozgen and A. Ozsahin** 321

Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot study: **R. Yoshimura, S. Kakihara, W. Umene-Nakano, A. Sugita, H. Hori, N. Ueda and J. Nakamura** 327

Short Communications

Placebo response to caffeine improves reaction time performance in sleepy people: **C. Anderson and J. A. Horne** 333

Pregabalin in the discontinuation of long-term benzodiazepines' use: **P. Oulis, G. Konstantakopoulos, A. V. Kouzoupis, V. G. Masdrakis, N. A. Karakatsanis, E. Karapoulios, K. A. Kontoangelos and G. N. Papadimitriou** 337

Book Review

Performance Enhancing Medications and Drugs of Abuse: **B. E. Leonard** 341

Current Awareness in Human Psychopharmacology 343

Issue No. 5 July 2008

Review Articles

The loudness dependence of the auditory evoked potential (LDAEP) as an *in vivo* biomarker of central serotonergic function in humans: rationale, evaluation and review of findings: **B. V. O'Neill, R. J. Croft and P. J. Nathan** 355

Is major depressive disorder a metabolic encephalopathy?: **B. H. Harvey** 371

Research Articles

Next-day cognition, psychomotor function, and driving-related skills following nighttime administration of eszopiclone: **J. Boyle, L. Trick, S. Johnsen, J. Roach and R. Rubens** 385

The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: A double-blind crossover trial: **K. Iwamoto, M. Takahashi, Y. Nakamura, Y. Kawamura, R. Ishihara, Y. Uchiyama, K. Ebe, A. Noda, Y. Noda, K. Yoshida, T. Iidaka and N. Ozaki** 399

Executive function deficits in short-term abstinent cannabis users: **S. McHale and N. Hunt** 409

Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics: **G. Martinotti, S. Andreoli, M. Di Nicola, M. Di Giannantonio, M. Sarchiapone and L. Janiri** 417

The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine: **A. Fredrickson, P. J. Snyder, J. Cromer, E. Thomas, M. Lewis and P. Maruff** 425

Letters to the Editor

MAO-A dysfunctions and aggressive behaviors in patients with ADHD: **M. Angriman and S. Cortese** ... 437

5-HT functioning and aggression in children with ADHD and disruptive behaviour disorders: **F. D. Zepf and F. Poustka** 438

Current Awareness in Human Psychopharmacology 439

Issue No. 6 August 2008

Research Articles

Comparison of mania patients suitable for treatment trials versus clinical treatment: **A. Talamo, R. J. Baldessarini and F. Centorrino** 447

Effectiveness of antipsychotic polypharmacy for patients with treatment refractory schizophrenia: an open-label trial of olanzapine plus risperidone for those who failed to respond to a sequential treatment with olanzapine, quetiapine and risperidone: **T. Suzuki, H. Uchida, K. Watanabe, S. Nakajima, K. Nomura, H. Takeuchi, A. Tanabe, G. Yagi and H. Kashima** 455

Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial: **Z.-h. Chen, G.-h. Wang, X.-p. Wang, R.-y. Chen, H.-l. Wang, M.-h. Yang, Y.-x. Huo and H.-b. Mei** 465

Short Communication

Gender differences in metabolic monitoring of second-generation antipsychotic prescription: **H. Verdoux, S. Boulon and A. Cougnard** 471

Research Articles

Polydrug use, cannabis, and psychosis-like symptoms: **N. T van Dam, M. Earleywine and G. DiGiacomo** 475

A brief cannabis-associated problems questionnaire with less potential for bias: **J. M. Lavender, A. Looby and M. Earleywine** 487

Ecstasy-related deficits in the updating component of executive processes: **C. Montgomery and J. E. Fisk** 495

Comparison of craving and withdrawal among four combination nicotine treatments: **N. G. Schneider, C. Cortner, J. L. Gould, M. A. Koury and R. E. Olmstead** 513

Efficacy and tolerability of duloxetine in elderly patients with generalized anxiety disorder: a pooled analysis of four randomized, double-blind, placebo-controlled studies: **J. Davidson, C. Allgulander, M. H. Pollack, J. Hartford, J. S. Erickson, J. M. Russell, D. Perahia, M. M. Wohlreich, J. Carlson and J. Raskin** 519

Resolution of sexual dysfunction during acute treatment of major depression with milnacipran: **D. Baldwin, R. A. Moreno and M. Briley** 527

Short Communication

Identification of *CYP2D6* null variants among long-stay, chronic psychiatric inpatients: Is it strictly necessary?: **A. Fernández-Santander, C. Santiago, S. Díez-Durán, M. González, E. de Castro, J. Guijarro, F. Bandrés, A. Lucia and F. Gómez-Gallego** 533

Book Reviews

Glial Neurobiology: **B. E. Leonard** 537

Serotonin and Sleep: Molecular, Functional and Clinical Aspects: **B. E. Leonard** 538

Current Awareness in Human Psychopharmacology 541

Issue No. 7 October 2008

Short Communication

S-ketamine and GABA-A-receptor interaction in humans: an exploratory study with I-123-iomazenil SPECT: **A. Heinzel, R. Steinke, T. D. Poeppel, O. Grosser, B. Bogerts, H. Otto and G. Northoff** 549

Review Articles

Sedation and antihistamines: an update. Review of inter-drug differences using proportional impairment ratios: **K. McDonald, L. Trick and J. Boyle** 555

Circadian rhythm disturbances in depression: **A. Germain and D. J. Kupfer** 571

Research Articles

Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates: **U. Dannlowski, B. T. Baune, I. Böckermann, K. Domschke, S. Evers, V. Arolt, G. Hetzel and M. Rothermundt** 587

Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications: **J. M. Jerrell and P. M. Ramirez** 595

Benzodiazepine-induced reduction in activity mirrors decrements in cognitive and psychomotor performance: **J. Dawson, J. Boyle, N. Stanley, S. Johnsen, I. Hindmarch and D. J. Skene** 605

Factors potentiating the risk of mirtazapine-associated restless legs syndrome: **S.-W. Kim, I.-S. Shin, J.-M. Kim, K.-H. Park, T. Youn and J.-S. Yoon** 615

The effects of cigarette smoking and abstinence on auditory verbal learning: **K. Soar, L. Dawkins, H. Begum and A. C. Parrott** 621

Targeted scoring criteria reduce variance in global impressions: **S. D. Targum, J. Busner and A. H. Young** 629

Current Awareness in Human Psychopharmacology 635

Issue No. 8 December 2008

Research Articles

Predictors of response to sertraline in patients with major depression: **S. Morishita and T. Kinoshita** 647

Quetiapine augmentation in depressed patients with partial response to antidepressants: **J. S. Olver, S. Ignatiadis, P. Maruff, G. D. Burrows and T. R. Norman** 653

Are antidepressants warranted in the treatment of patients who present suicidal behavior?: **M. Raja and A. Azzoni** 661

Effects of dietary caffeine on EEG, performance and mood when rested and sleep restricted: **M. A. Keane and J. E. James** 669

Effects of modafinil on simulator driving and self-assessment of driving following sleep deprivation: **C. G. Gurtman, J. H. Broadbear and J. R. Redman** 681

Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers: **S. Otmani, A. Demazières, C. Staner, N. Jacob, T. Nir, N. Zisapel and L. Staner** 693

Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertraline: **R. Yoshimura, W. Umene-Nakano, N. Ueda, A. Ikenouchi-Sugita, H. Hori and J. Nakamura** 707

Long-term sustained benefits of clozapine treatment in refractory early onset schizophrenia: A retrospective study in Korean children and adolescents: **Y. Kim, B.-N. Kim, S.-C. Cho, J.-W. Kim and M.-S. Shin** 715

Book Review

Pharmacology of Bipolar Disorders: **B. E. Leonard** 723

Erratum 725

Current Awareness in Human Psychopharmacology 727

Author Index 735

Keyword Index 737

Volume Contents iii

Supplement 1 January 2008 pp. S1–S52

Special Issue: Key Issues in the Safety and Tolerability of Psychiatric Drugs
Guest Editors: Dr. Peter M. Haddad and Dr. Serdar M. Dursun

Improving drug safety and tolerability in psychiatric clinical practice: **P. M. Haddad and S. M. Dursun** 1

Cardiac side effects of psychiatric drugs: **P. Mackin** 3

Neurological complications of psychiatric drugs: clinical features and management: **P. M. Haddad and S. M. Dursun** 15

Haematological toxicity of drugs used in psychiatry: **R. J. Flanagan and L. Dunk** 27

Fatal toxicity of drugs used in psychiatry: **R. J. Flanagan** 43